We then mapped patient-specific tau-PET to cognitive-domain-specific brain activation maps and tested whether determining baseline tau-PET in regions involved in a given cognitive domain improves the prediction of cognitive-domain-specific decline compared to conventional tau-PET metrics (i.e., global/temporal-lobe tau-PET standardized uptake value ratios [SUVRs]) that have been suggested as prognostic markers in AD [9, 10]. The gene discussed is MAPT; the disease is Alzheimer disease.